Bengt Glimelius

List of Publications by Year
in descending order

321 papers	29,492 citations	14614 66 h-index	5364 164 g-index
324 all docs	324 docs citations	324 times ranked	25812 citing authors

#	Article	IF	Citations
1	Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer. New England Journal of Medicine, 2001, 345, 638-646.	13.9	3,840
2	A pathology atlas of the human cancer transcriptome. Science, 2017, 357, .	6.0	2,570
3	Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer. New England Journal of Medicine, 1997, 336, 980-987.	13.9	2,420
4	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology, 2012, 23, 2479-2516.	0.6	1,233
5	Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2013, 14, 1208-1215.	5.1	1,017
6	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi81-vi88.	0.6	833
7	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA - Journal of the American Medical Association, 2016, 315, 1844.	3.8	801
8	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 29-42.	5.1	739
9	Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Annals of Oncology, 1997, 8, 163-168.	0.6	735
10	Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Annals of Oncology, 1996, 7, 593-600.	0.6	696
11	Preoperative or postoperative irradiation in adenocarcinoma of the rectum. Diseases of the Colon and Rectum, 1993, 36, 564-572.	0.7	482
12	Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. Journal of Clinical Oncology, 2012, 30, 1755-1762.	0.8	482
13	Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncology, The, 2017, 18, 336-346.	5.1	447
14	Preoperative irradiation affects functional results after surgery for rectal cancer. Diseases of the Colon and Rectum, 1998, 41, 543-549.	0.7	419
15	Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer. Journal of Clinical Oncology, 2008, 26, 3687-3694.	0.8	412
16	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). Journal of Clinical Oncology, 2012, 30, 1620-1627.	0.8	357
17	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. European Journal of Cancer, 2014, 50, 1.e1-1.e34.	1.3	349
18	Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Annals of Oncology, 2015, 26, 463-476.	0.6	327

#	Article	IF	Citations
19	Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Annals of Oncology, 2015, 26, 696-701.	0.6	302
20	Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiotherapy and Oncology, 2009, 92, 148-163.	0.3	275
21	Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta OncolÃ³gica, 2015, 54, 5-16.	0.8	270
22	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer â€“ the RAPIDO trial. BMC Cancer, 2013, 13, 279.	1.1	237
23	Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. British Journal of Surgery, 2010, 97, 580-587.	0.1	233
24	Short-course preoperative radiotherapy with delayed surgery in rectal cancer â€“ A retrospective study. Radiotherapy and Oncology, 2008, 87, 343-349.	0.3	199
25	Late adverse effects of radiation therapy for rectal cancer â€“ a systematic overview. Acta OncolÃ³gica, 2007, 46, 504-516.	0.8	195
26	Late adverse effects of short-course preoperative radiotherapy in rectal cancer. British Journal of Surgery, 2006, 93, 1519-1525.	0.1	193
27	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2019, 269, 520-529.	2.1	189
28	A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nature Genetics, 2010, 42, 1126-1130.	9.4	177
29	Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells. PLoS ONE, 2014, 9, e94621.	1.1	177
30	Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. British Journal of Surgery, 2015, 102, 972-978.	0.1	173
31	Changing strategy for rectal cancer is associated with improved outcome. British Journal of Surgery, 2003, 86, 379-384.	0.1	158
32	Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiotherapy and Oncology, 1997, 43, 133-137.	0.3	152
33	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	9.4	147
34	Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Annals of Oncology, 1995, 6, 267-274.	0.6	141
35	Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer, 1994, 73, 556-562.	2.0	133
36	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2018, 19, 562-578.	5.1	133

#	Article	IF	Citations
37	Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer â€“ Results of the international randomized RAPIDO-trial. Radiotherapy and Oncology, 2020, 147, 75-83.	0.3	132
38	Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer, 2009, 115, 4679-4687.	2.0	128
39	Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish Population. Diseases of the Colon and Rectum, 2018, 61, 1016-1025.	0.7	127
40	Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. European Journal of Cancer, 2016, 53, 155-162.	1.3	123
41	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. British Journal of Cancer, 2017, 117, 1478-1485.	2.9	118
42	Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics Journal, 2011, 11, 61-71.	0.9	108
43	Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgeryÂÂ±Âa fluoropyrimidine and surgeryÂ+Âa fluoropyrimidineÂÂ±Âoxaliplatin. European Journal of Surgical Oncology, 2015, 41, 713-723.	0.5	106
44	Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncology, The, 2019, 20, 74-87.	5.1	98
45	Is England closing the international gap in cancer survival?. British Journal of Cancer, 2015, 113, 848-860.	2.9	97
46	Maternal and perinatal risk factors for childhood brain tumors (Sweden). Cancer Causes and Control, 1996, 7, 437-448.	0.8	96
47	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	2.6	96
48	Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta OncolÃ³gica, 2005, 44, 904-912.	0.8	94
49	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	5.8	94
50	Local recurrences after surgical treatment for rectal carcinoma. Acta Chirurgica Scandinavica, 1984, 150, 331-5.	0.2	94
51	Tumour regression after radiotherapy for rectal cancer â€“ Results from the randomised Stockholm III trial. Radiotherapy and Oncology, 2019, 135, 178-186.	0.3	93
52	The â€˜goodâ€™, the â€˜badâ€™, and the â€˜uglyâ€™ rectal cancers. Acta OncolÃ³gica, 2008, 47, 5-8.	0.8	91
53	Population-based data from the Swedish Colon Cancer Registry. British Journal of Surgery, 2013, 100, 1100-1107.	0.1	91
54	High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. PLoS ONE, 2015, 10, e0131046.	1.1	91

#	Article	IF	Citations
55	Late Patient-Reported Toxicity After Preoperative Radiotherapy or Chemoradiotherapy in Nonresectable Rectal Cancer: Results From a Randomized Phase III Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1017-1024.	0.4	87
56	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v82-v86.	0.6	86
57	Implementation of pencil kernel and depth penetration algorithms for treatment planning of proton beams. Physics in Medicine and Biology, 2000, 45, 9-27.	1.6	84
58	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.. Journal of Clinical Oncology, 2020, 38, 4006-4006.	0.8	84
59	Individual Psychosocial Support for Breast Cancer Patients. Cancer Nursing, 2007, 30, E10-E19.	0.7	83
60	Number of patients potentially eligible for proton therapy. Acta OncolÃ³gica, 2005, 44, 836-849.	0.8	80
61	Time trends, improvements and national auditing of rectal cancer management over an 18â€year period. Colorectal Disease, 2015, 17, O168-79.	0.7	80
62	Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematological Oncology, 1993, 11, 187-193.	0.8	79
63	Multicenter Phase II Study of Nordic Fluorouracil and Folinic Acid Bolus Schedule Combined With Oxaliplatin As First-Line Treatment of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 31-38.	0.8	76
64	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175.	5.8	75
65	Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data metaâ€analysis of 22 RCTs. Psycho-Oncology, 2018, 27, 1150-1161.	1.0	74
66	Detection of tumor-specific cytotoxic drug activityIN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. International Journal of Cancer, 1994, 56, 715-720.	2.3	71
67	Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx^{Â®}): a placebo-controlled randomised phase II study (PLIANT). Acta OncolÃ³gica, 2018, 57, 393-402.	0.8	69
68	Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Annals of Oncology, 1993, 4, 235-240.	0.6	67
69	Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study. Annals of Oncology, 2013, 24, 160-165.	0.6	67
70	Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Annals of Oncology, 2013, 24, 2354-2360.	0.6	65
71	Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?. Journal of Clinical Oncology, 2016, 34, 1297-1299.	0.8	65
72	Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Annals of Oncology, 2019, 30, 1088-1095.	0.6	65

#	Article	IF	Citations
73	International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiotherapy and Oncology, 2020, 148, 213-215.	0.3	65
74	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Annals of Oncology, 2016, 27, 1557-1565.	0.6	64
75	Bolus injection (2â€“4min) versus short-term (10â€“20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. European Journal of Cancer, 1998, 34, 674-678.	1.3	63
76	EURECCA consensus conference highlights about rectal cancer clinical management: The radiation oncologistâ€™s expert review. Radiotherapy and Oncology, 2014, 110, 195-198.	0.3	61
77	Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). British Journal of Cancer, 2016, 115, 281-289.	2.9	61
78	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. Journal of Clinical Oncology, 2013, 31, LBA4003-LBA4003.	0.8	61
79	Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget, 2016, 7, 75013-75022.	0.8	61
80	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751.	5.8	58
81	Epstein-Barr Virus Distribution in Hodgkin's Disease in an Unselected Swedish Population. Acta OncolÃ³gica, 1999, 38, 425-429.	0.8	57
82	Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv54-iv56.	0.6	56
83	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer, 2014, 50, 2983-2993.	1.3	56
84	Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer, 2017, 116, 1271-1278.	2.9	55
85	Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Journal of Clinical Oncology, 2007, 25, LBA5-LBA5.	0.8	54
86	Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach â€“ present status. Scandinavian Journal of Gastroenterology, 2012, 47, 296-314.	0.6	53
87	Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells. International Journal of Oncology, 2017, 50, 5-14.	1.4	53
88	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Human Molecular Genetics, 2016, 25, 1663-1676.	1.4	52
89	U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta OncolÃ³gica, 2018, 57, 187-194.	0.8	52
90	Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival. BMC Cancer, 2011, 11, 438.	1.1	51

#	Article	IF	Citations
91	Neo-adjuvant radiotherapy in rectal cancer. World Journal of Gastroenterology, 2013, 19, 8489.	1.4	51
92	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncology, The, 2018, 19, e151-e160.	5.1	51
93	Health-related quality of life and distress in cancer patients: results from a large randomised study. British Journal of Cancer, 2008, 99, 1975-1983.	2.9	49
94	Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Annals of Oncology, 2011, 22, 1717-1725.	0.6	49
95	Anal carcinoma â€“ Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiotherapy and Oncology, 2014, 113, 352-358.	0.3	49
96	Lymphovascular and perineural invasion in stage II rectal cancer: a report from the Swedish colorectal cancer registry. Acta OncolÃ³gica, 2016, 55, 1418-1424.	0.8	49
97	Two countries â€“ Two treatment strategies for rectal cancer. Radiotherapy and Oncology, 2016, 121, 357-363.	0.3	48
98	Prognostic significance of flow cytometry studies in B-cell non-hodgkin lymphoma. Hematological Oncology, 1990, 8, 1-12.	0.8	47
99	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. British Journal of Cancer, 2018, 118, 1609-1616.	2.9	47
100	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. Journal of the National Cancer Institute, 2014, 106, .	3.0	46
101	The potential for improved outcome in patients with hepatic metastases from colon cancer: a population-based study. European Journal of Surgical Oncology, 2004, 30, 834-841.	0.5	44
102	Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?. Frontiers in Oncology, 2014, 4, 50.	1.3	43
103	Risk of second primary cancer in patients treated with radiotherapy for rectal cancer. British Journal of Surgery, 2017, 104, 278-287.	0.1	43
104	Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 376-388.	3.7	43
105	Extracellular matrices in multicellular spheroids of human glioma origin: Increased incorporation of proteoglycans and fibronectin as compared to monolayer cultures. Apmis, 1988, 96, 433-444.	0.9	41
106	A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer, 1994, 73, 445-454.	2.0	41
107	Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. British Journal of Cancer, 2012, 107, 189-194.	2.9	41
108	A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of Oncology, 2008, 19, 909-914.	0.6	40

#	Article	IF	Citations
109	Consequences of a high incidence of microsatellite instability and BRAFâ€mutated tumors: A populationâ€based cohort of metastatic colorectal cancer patients. Cancer Medicine, 2019, 8, 3623-3635.	1.3	40
110	Administration of adjuvant chemotherapy for stage <scp>IIâ€III</scp> colon cancer patients: An European populationâ€based study. International Journal of Cancer, 2018, 142, 1480-1489.	2.3	39
111	[¹⁸F] FDG PET in Gastric Non-Hodgkin's Lymphoma. Acta OncolÃ³gica, 1997, 36, 577-584.	0.8	38
112	Pregnancy and risk of non-Hodgkin's lymphoma: A prospective study. , 1997, 70, 155-158.		38
113	Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. Upsala Journal of Medical Sciences, 2012, 117, 225-236.	0.4	38
114	ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 IntergroupÂ randomized phase III clinical trial.. Journal of Clinical Oncology, 2012, 30, 8002-8002.	0.8	38
115	Different Intravenous Administration Techniques for 5-Fluorouracil Pharmacokinetics and Pharmacodynamic Effects. Acta OncolÃ³gica, 1996, 35, 207-212.	0.8	36
116	Perioperative Radiotherapy in Rectal Cancer. Acta OncolÃ³gica, 1999, 38, 23-32.	0.8	36
117	Potential Gains Using High-Energy Protons for Therapy of Malignant Tumours. Acta OncolÃ³gica, 1999, 38, 137-145.	0.8	36
118	The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics Journal, 2014, 14, 424-431.	0.9	36
119	General Condition of Asymptomatic Patients with Advanced Colorectal Cancer Receiving Palliative Chemotherapy: A longitudinal study. Acta OncolÃ³gica, 1992, 31, 645-651.	0.8	35
120	Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. , 1997, 72, 394-397.		35
121	The Swedish Council on Technology Assessment in Health Care (SBU) Systematic Overview of Chemotherapy Effects in Some Major Tumour Types - Summary and Conclusions. Acta OncolÃ³gica, 2001, 40, 135-154.	0.8	35
122	Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer, 2015, 15, 125.	1.1	35
123	CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup. Frontiers in Oncology, 2020, 10, 8.	1.3	35
124	Treatment of Hodgkin's Disease: The Swedish National Care Programme Experience. Leukemia and Lymphoma, 1996, 21, 71-78.	0.6	34
125	Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma. , 2000, 85, 639-642.		34
126	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research, 2018, 78, 4086-4096.	0.4	34

#	Article	IF	Citations
127	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. International Journal of Cancer, 2020, 146, 94-102.	2.3	34
128	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treatment Reviews, 2021, 98, 102218.	3.4	33
129	Does exercise intensity matter for fatigue during (neoâ€)adjuvant cancer treatment? The Physâ€Can randomized clinical trial. Scandinavian Journal of Medicine and Science in Sports, 2021, 31, 1144-1159.	1.3	32
130	Chemotherapy in Addition to Preoperative Radiotherapy in Locally Advanced Rectal Cancer â€“ A Systematic Overview. Reviews on Recent Clinical Trials, 2008, 3, 204-211.	0.4	32
131	Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. European Radiology, 2022, 32, 4991-5003.	2.3	32
132	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. Journal of Clinical Oncology, 2013, 31, LBA4003-LBA4003.	0.8	31
133	Lymphoma Incidence in a Swedish County During 1969â€“1987. Acta OncolÃ³gica, 1992, 31, 275-282.	0.8	30
134	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. British Journal of Cancer, 2018, 118, 947-954.	2.9	30
135	Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. Oncotarget, 0, 7, 41948-41958.	0.8	30
136	Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. Cancer Research, 2017, 77, 1730-1740.	0.4	29
137	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	1.3	29
138	Radiotherapy in rectal cancer. British Medical Bulletin, 2002, 64, 141-157.	2.7	28
139	Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Annals of Oncology, 2002, 13, 1868-1873.	0.6	28
140	Genetic overlap between autoimmune diseases and nonâ€Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863.	0.6	28
141	Chemotherapy in the treatment of cancer of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 235-241.	2.0	27
142	Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients. Acta OncolÃ³gica, 2013, 52, 528-537.	0.8	27
143	On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery. Upsala Journal of Medical Sciences, 2017, 122, 1-10.	0.4	27
144	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.. Journal of Clinical Oncology, 2012, 30, 3508-3508.	0.8	27

#	Article	IF	Citations
145	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS ONE, 2017, 12, e0182512.	1.1	27
146	Is History of Squamous-Cell Skin Cancer a Marker of Poor Prognosis in Patients with Cancer?. Annals of Internal Medicine, 1999, 131, 655.	2.0	26
147	Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer. Drug Safety, 2005, 28, 417-433.	1.4	26
148	Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinico-pathological and immuno-histochemical population-based study of 32 patients. , 1997, 71, 510-516.		25
149	Evaluation of Clinical Benefit of Chemotherapy in Patients with Upper Gastrointestinal Cancer. Acta OncolÃ³gica, 1998, 37, 651-659.	0.8	25
150	Recurrence Risk after Radical Colorectal Cancer Surgeryâ€"Less Than before, But How High Is It?. Cancers, 2020, 12, 3308.	1.7	25
151	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. EBioMedicine, 2021, 65, 103269.	2.7	25
152	Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.. Journal of Clinical Oncology, 2014, 32, 4001-4001.	0.8	25
153	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of Oncology, 2015, 26, 1936-1941.	0.6	24
154	The Swedish National Care Programme for Anal Carcinoma: Implementation and Overall Results. Acta OncolÃ³gica, 1998, 37, 25-32.	0.8	23
155	Therapy with Radiopharmaceuticals. Acta OncolÃ³gica, 2002, 41, 623-628.	0.8	23
156	Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer. Scientific Reports, 2016, 6, 36149.	1.6	23
157	Anxiety, Depression and Worry in Gastrointestinal Cancer Patients Attending Medical Follow-Up Control Visits. Acta OncolÃ³gica, 1996, 35, 411-416.	0.8	22
158	Prognostic relevance of serumâ€markers in relation to histopathology, stage and initial symptoms in advanced lowâ€grade nonâ€Hodgkin lymphomas. European Journal of Haematology, 1988, 40, 289-298.	1.1	22
159	A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Annals of Oncology, 2010, 21, 1020-1026.	0.6	22
160	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta OncolÃ³gica, 2020, 59, 417-426.	0.8	22
161	Ultraviolet Light and Non-Hodgkin's Lymphoma. Acta OncolÃ³gica, 1996, 35, 655-657.	0.8	21
162	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood, 2018, 131, 2541-2551.	0.6	21

#	Article	IF	Citations
163	A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer. Cancers, 2021, 13, 16.	1.7	21
164	ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Pancreatology, 2016, 16, S63.	0.5	20
165	Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. Clinical Colorectal Cancer, 2018, 17, e129-e142.	1.0	20
166	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. Journal of Clinical Oncology, 2020, 38, 4516-4516.	0.8	20
167	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 2019, 23, 1-88.	1.3	20
168	Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer â€“ The RAPIDO trial. Radiotherapy and Oncology, 2022, 171, 69-76.	0.3	20
169	Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: The Swedish National Care Programme Experience. Annals of Oncology, 1994, 5, 809-816.	0.6	19
170	Adjuvant chemotherapy in rectal cancerâ€”an issue or a nonissue?. Annals of Oncology, 2010, 21, 1739-1741.	0.6	19
171	Preoperative treatment selection in rectal cancer: AÂpopulation-based cohort study. European Journal of Surgical Oncology, 2014, 40, 1782-1788.	0.5	19
172	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 2018, 119, 1332-1338.	2.9	19
173	Radiotherapy in Addition to Radical Surgery in Rectal Cancer. Acta OncolÃ³gica, 1995, 34, 565-570.	0.8	18
174	Radiation Therapy Through Activation of Stable Nuclides. Acta OncolÃ³gica, 2002, 41, 629-634.	0.8	18
175	Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort. Annals of Surgical Oncology, 2020, 27, 1036-1045.	0.7	18
176	Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. PLoS ONE, 2014, 9, e87746.	1.1	18
177	A Comprehensive Cancer Care Project to Improve the Overall Situation of Patients Receiving Intensive Chemotherapy. Journal of Psychosocial Oncology, 1993, 11, 17-40.	0.6	17
178	A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival. BMC Medical Genetics, 2014, 15, 113.	2.1	17
179	¹⁵O-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusable Tissue Fraction in Colorectal Cancer Metastases. Journal of Nuclear Medicine, 2015, 56, 1144-1149.	2.8	17
180	Postoperative complications in relation to overall treatment time in patients with rectal cancer receiving neoadjuvant radiotherapy. British Journal of Surgery, 2019, 106, 1248-1256.	0.1	16

#	Article	IF	Citations
181	No excess longâ€term mortality in stage Iâ€IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology, 2020, 188, 685-691.	1.2	16
182	Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer. Acta OncolÃ³gica, 2021, 60, 842-849.	0.8	16
183	A comparative study of proliferation-associated parameters in b-cell non-hodgkin lymphoma. Hematological Oncology, 2006, 9, 287-298.	0.8	15
184	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 2016, 37, 852-857.	1.3	15
185	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187.	1.1	15
186	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. Nature Communications, 2018, 9, 4182.	5.8	15
187	Evaluation of the antibody response to the EBV proteome in EBVâ€associated classical Hodgkin lymphoma. International Journal of Cancer, 2020, 147, 608-618.	2.3	15
188	HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.. Journal of Clinical Oncology, 2013, 31, 4006-4006.	0.8	15
189	KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer. Frontiers in Oncology, 2022, 12, 826073.	1.3	15
190	Improved Care of Patients with Small Cell Lung Cancer Nutritional and Quality of Life Aspects. Acta OncolÃ³gica, 1992, 31, 823-831.	0.8	14
191	Primarily asymptomatic lowâ€grade nonâ€Hodgkin lymphomas: Prediction of symptomâ€free survival and total survival. European Journal of Haematology, 1989, 43, 332-338.	1.1	14
192	Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer. European Journal of Surgical Oncology, 2017, 43, 311-321.	0.5	14
193	Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients. Cancers, 2020, 12, 2289.	1.7	14
194	The Immune Landscape of Colorectal Cancer. Cancers, 2021, 13, 5545.	1.7	14
195	Swedish Cancer Society Radiation Therapy Research Investigation. Acta OncolÃ³gica, 2002, 41, 596-603.	0.8	13
196	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer, 2017, 81, 26-35.	1.3	13
197	What conclusions can be drawn from the Stockholm III rectal cancer trial in the era of watch and wait?. Acta OncolÃ³gica, 2017, 56, 1139-1142.	0.8	13
198	Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer, 2017, 17, 548.	1.1	13

#	Article	IF	Citations
199	Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591881835.	1.4	13
200	Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. Cancers, 2020, 12, 3238.	1.7	13
201	Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapyâ€"The Randomized NORDIC9-Study. Cancers, 2021, 13, 2604.	1.7	13
202	Methyl-Gag, Ifosfamide, Methotrexate and Etoposide (Mime) as Salvage Therapy for Non-Hodgkin's Lymphomasa Swedish national prospective study. Acta OncolÃ³gica, 1996, 35, 165-170.	0.8	12
203	Infradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. European Journal of Haematology, 1997, 59, 31-37.	1.1	12
204	Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases. European Journal of Surgical Oncology, 2018, 44, 983-990.	0.5	12
205	Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. Current Opinion in Oncology, 2020, 32, 377-383.	1.1	12
206	Diagnostics of Malignant Lymphomas with Ultrasound Guided 1.2 MM Biopsy-Gun. Acta OncolÃ³gica, 1994, 33, 33-37.	0.8	11
207	Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. International Journal of Cancer, 1995, 63, 356-360.	2.3	11
208	Oncology in the Nordic Countries: The Role of Acta Oncologica?. Acta OncolÃ³gica, 2002, 41, 3-5.	0.8	11
209	Methylâ€GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study. European Journal of Haematology, 1998, 60, 166-171.	1.1	11
210	Prognostic factors in patients with loco-regionally advanced gastric cancer. World Journal of Surgical Oncology, 2017, 15, 172.	0.8	11
211	Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta OncolÃ³gica, 2020, 59, 284-290.	0.8	11
212	Moderators of the effect of psychosocial interventions on fatigue in women with breast cancer and men with prostate cancer: Individual patient data metaâ€anâ€alyses. Psycho-Oncology, 2020, 29, 1772-1785.	1.0	11
213	The 50-year anniversary of Acta Oncologica. Acta OncolÃ³gica, 2014, 53, 1-2.	0.8	10
214	Development of anxiety, depression and health-related quality of life in oncology patients without initial symptoms according to the Hospital Anxiety and Depression Scale â€“ a comparative study. Acta OncolÃ³gica, 2017, 56, 1094-1102.	0.8	10
215	Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register. Radiotherapy and Oncology, 2018, 126, 424-430.	0.3	10
216	Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 395-405.	1.4	10

#	Article	IF	Citations
217	Preoperative radiotherapy or chemoradiotherapy in rectal cancer â€“ Is survival improved? An update of the â€œNordicâ€•LARC study in non-resectable cancers. Radiotherapy and Oncology, 2018, 127, 392-395.	0.3	10
218	Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. Radiotherapy and Oncology, 2019, 136, 106-112.	0.3	10
219	Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery?. Radiotherapy and Oncology, 2021, 157, 70-77.	0.3	10
220	Clinicopathological factors associated with tumourâ€specific mutation detection in plasma of patients with <scp>RAS</scp>â€mutated or <scp>BRAF</scp>â€mutated metastatic colorectal cancer. International Journal of Cancer, 2021, 149, 1385-1397.	2.3	10
221	What is most relevant in preoperative rectal cancer chemoradiotherapy â€“ the chemotherapy, the radiation dose or the timing to surgery?. Acta OncolÃ³gica, 2016, 55, 1381-1385.	0.8	9
222	Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 2018, 118, 1084-1088.	2.9	9
223	And they lived happily ever afterâ€¦ The marriage of Nordic Association for Clinical Physics and Acta Oncologica. Acta OncolÃ³gica, 2011, 50, 835-837.	0.8	8
224	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer, 2015, 137, 2470-2477.	2.3	8
225	Impact of pre-treatment patient-related selection parameters on outcome in rectal cancer. European Journal of Surgical Oncology, 2016, 42, 1667-1673.	0.5	8
226	Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. Acta OncolÃ³gica, 2020, 59, 1016-1023.	0.8	8
227	Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. British Journal of Cancer, 2022, 126, 48-56.	2.9	8
228	Sensitizing and Protective Substances in Radiation Therapy and Predictive Assays. Acta OncolÃ³gica, 2002, 41, 615-622.	0.8	7
229	50 years with Acta Oncologica. Acta OncolÃ³gica, 2013, 52, 1-2.	0.8	7
230	Effects and moderators of coping skills training on symptoms of depression and anxiety in patients with cancer: Aggregate data and individual patient data meta-analyses. Clinical Psychology Review, 2020, 80, 101882.	6.0	7
231	Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1022-1031.	0.4	7
232	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2014, 32, 3575-3575.	0.8	7
233	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. Oncotarget, 2016, 7, 59441-59457.	0.8	7
234	Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 342-351.	1.1	7

#	Article	IF	Citations
235	The Value of Adjuvant Therapy after Radical Surgery for Colorectal Cancer. Annals of Medicine, 1992, 24, 9-14.	1.5	6
236	Is the benefit of oxaliplatin in rectal cancer clinically relevant?. Lancet Oncology, The, 2015, 16, 883-885.	5.1	6
237	Adjuvant chemotherapy for patients with rectal cancer â€“ will the controversy be resolved?. Acta OncolÃ³gica, 2015, 54, 433-436.	0.8	6
238	Need for adjuvant chemotherapy after colon cancer surgery â€“ has it decreased?. Acta OncolÃ³gica, 2017, 56, 629-633.	0.8	6
239	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. Frontiers in Oncology, 2019, 9, 1539.	1.3	6
240	Accurate population-based model for individual prediction of colon cancer recurrence. Acta OncolÃ³gica, 2021, 60, 1241-1249.	0.8	6
241	Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 993-1002.	0.4	6
242	Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy. Journal of Clinical Oncology, 2022, 40, 1487-1496.	0.8	6
243	A clinical study of CA-50 as a tumour marker for monitoring of colorectal cancer. Medical Oncology and Tumor Pharmacotherapy, 1988, 5, 165-71.	1.0	6
244	Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study. Cancers, 2022, 14, 1713.	1.7	6
245	Lowâ€dose aspirin use and colorectal cancer survival in 32,195 patientsâ€”A national cohort study. Cancer Medicine, 2023, 12, 315-324.	1.3	6
246	Immunophenotype analysis of Bâ€CLL lymphoma and immunocytoma. Apmis, 1989, 97, 1025-1032.	0.9	5
247	Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer. Translational Oncology, 2016, 9, 251-255.	1.7	5
248	Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers. European Journal of Surgical Oncology, 2018, 44, 1858-1864.	0.5	5
249	Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer. British Journal of Cancer, 2019, 121, 303-311.	2.9	5
250	The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.. Journal of Clinical Oncology, 2012, 30, 678-678.	0.8	5
251	Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.. Journal of Clinical Oncology, 2015, 33, 3514-3514.	0.8	5
252	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 2021, 13, 5758.	1.7	5

#	Article	IF	Citations
253	Radioimmunolocalization of Hepatic Metastases and Subcutaneous Xenografts from a Human Colonic Cancer: In the Nude Rat: Aspects of Tumour Implantation Site and Mode of Antibody Administration. Acta OncolÃ³gica, 1993, 32, 877-885.	0.8	4
254	Acta Oncologicaâ€"Greater Attractiveness. Acta OncolÃ³gica, 2003, 42, 799-799.	0.8	4
255	A new volume of Acta Oncologica. Acta OncolÃ³gica, 2011, 50, 3-5.	0.8	4
256	Adjuvant chemotherapy for rectal cancer. Lancet Oncology, The, 2014, 15, e194-e195.	5.1	4
257	Does shared decision making exist in oncologic practice?. Acta OncolÃ³gica, 2016, 55, 125-128.	0.8	4
258	Mucinous rectal cancers: clinical features and prognosis in a population-based cohort. BJS Open, 2022, 6, .	0.7	4
259	Pre-chemotherapy nervousness as a marker for anticipatory nausea: A case of a non-causal predictor. Psycho-Oncology, 1993, 2, 33-41.	1.0	3
260	DNA CONTENT IN CARCINOMA OF THE RECTUM AND RECTOSIGMOID. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1985, 93A, 277-284.	0.3	3
261	Acta Oncologica and a new generation of scientists in oncology. Acta OncolÃ³gica, 2014, 53, 849-851.	0.8	3
262	More than 1000 new manuscripts in 2017. Acta OncolÃ³gica, 2018, 57, 174-175.	0.8	3
263	Forty-five years in oncology, 25 years with Acta Oncologica. Acta OncolÃ³gica, 2018, 57, 1593-1598.	0.8	3
264	Do we make progress in elderly patients with metastatic colorectal cancer?. Acta OncolÃ³gica, 2018, 57, 1422-1426.	0.8	3
265	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. Journal of Clinical Oncology, 2014, 32, 489-489.	0.8	3
266	Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial. BJS Open, 2021, 5, .	0.7	3
267	Cytostatic Drug Therapy in Disseminated Colorectal Cancer. Scandinavian Journal of Gastroenterology, 1988, 23, 181-189.	0.6	2
268	Authors' reply: Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy (Br J Surg 2008; 95: 206â€"213). British Journal of Surgery, 2008, 95, 803-803.	0.1	2
269	Life of Pi. Acta OncolÃ³gica, 2011, 50, 1139-1141.	0.8	2
270	Any progress in pancreatic cancer?. Acta OncolÃ³gica, 2016, 55, 255-258.	0.8	2

#	Article	IF	Citations
271	Tell all the good news as soon as possible. Acta OncolÃ³gica, 2016, 55, 1067-1068.	0.8	2
272	The PLIANT trial gives trustworthy data. Acta OncolÃ³gica, 2018, 57, 864-866.	0.8	2
273	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. European Journal of Cancer, 2018, 96, 115-124.	1.3	2
274	O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors. Annals of Oncology, 2020, 31, 239.	0.6	2
275	TOSCAâ€"a delicious Swedish almond cake, an Italian opera and an Italian trial with important new data. Annals of Oncology, 2021, 32, 6-8.	0.6	2
276	Interpreting the RAPIDO trial: factors to consider â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e90-e91.	5.1	2
277	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. Clinical Colorectal Cancer, 2021, 20, 236-244.	1.0	2
278	Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group.. Journal of Clinical Oncology, 2012, 30, 3538-3538.	0.8	2
279	Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.. Journal of Clinical Oncology, 2014, 32, 465-465.	0.8	2
280	Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors.. Journal of Clinical Oncology, 2020, 38, 7037-7037.	0.8	2
281	RESPONSE: Re: Sun Exposure and Mortality From Melanoma. Journal of the National Cancer Institute, 2005, 97, 1160-1161.	3.0	1
282	Adjuvant chemotherapy. European Journal of Cancer, Supplement, 2013, 11, 72-79.	2.2	1
283	Whatâ€™s new about Acta Oncologica for 2016?. Acta OncolÃ³gica, 2015, 54, 1703-1705.	0.8	1
284	What treatments should be skipped or intensified in localized rectal cancer?. Future Oncology, 2018, 14, 313-318.	1.1	1
285	NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC). Annals of Oncology, 2018, 29, viii151.	0.6	1
286	Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer. Acta OncolÃ³gica, 2019, 58, 395-397.	0.8	1
287	An audit of performance, interpretation, and influence of pretherapeutic MRI in rectal cancer: a Swedish population-based cohort study. Acta Radiologica, 2019, 60, 955-961.	0.5	1
288	Quality of life assessments in clinical practice using either the EORTC-QLQ-C30 or the SEIOQL-DW: a randomized study. Journal of Patient-Reported Outcomes, 2021, 5, 58.	0.9	1

#	Article	IF	Citations
289	Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinico-pathological and immuno-histochemical population-based study of 32 patients. , 1997, 71, 510.		1
290	Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. , 1994, 73, 556.		1
291	Prognostic impact of preoperative plasma tissue inhibitor of metalloproteinase 1 (pTIMP-1) in colorectal cancer (CRC) patients (Pts): A pooled analysis of 1,024 stage II/III pts.. Journal of Clinical Oncology, 2012, 30, 3576-3576.	0.8	1
292	International expertsâ€™ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 4053-4053.	0.8	1
293	Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.. Journal of Clinical Oncology, 2014, 32, 3562-3562.	0.8	1
294	Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.. Journal of Clinical Oncology, 2015, 33, 235-235.	0.8	1
295	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2015, 33, 581-581.	0.8	1
296	The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint.. Journal of Clinical Oncology, 2012, 30, TPS10632-TPS10632.	0.8	1
297	Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.. Journal of Clinical Oncology, 2014, 32, 4024-4024.	0.8	1
298	Authors' reply: Radiological findings do not support lateral residual tumour as a major cause of local recurrence of rectal cancer (Br J Surg 2006; 93: 113â€“119). British Journal of Surgery, 2006, 93, 507-507.	0.1	0
299	Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?. Current Colorectal Cancer Reports, 2013, 9, 116-125.	1.0	0
300	Reply to D.J. Sargent et al. Journal of Clinical Oncology, 2016, 34, 3713-3714.	0.8	0
301	Reply to C.F. Hess et al. Journal of Clinical Oncology, 2017, 35, 374-374.	0.8	0
302	How Long to Wait After Preoperative Radio(Chemo) Therapy to Perform Surgery?. , 2018, , 463-474.		0
303	ASO Author Reflections: Emerging Risk Factors in Colon Cancerâ€”End of the Line for Clinomics?. Annals of Surgical Oncology, 2020, 27, 1046-1047.	0.7	0
304	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
305	Pretreatment MRI in Primary Rectal Cancer as a Predictor for Oncological Outcomes After Surgery for Local Recurrence. Anticancer Research, 2021, 41, 2459-2465.	0.5	0
306	Risk of EBV-Positive Hodgkin Lymphoma Varies Over 30-Fold by HLA Class I Genotype and History of Infectious Mononucleosis.. Blood, 2009, 114, 269-269.	0.6	0

#	Article	IF	Citations
307	Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2012, 30, 3548-3548.	0.8	0
308	The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2012, 30, e14088-e14088.	0.8	0
309	Plasma levels of TIMP-1 in chemo-naive patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study.. Journal of Clinical Oncology, 2013, 31, 392-392.	0.8	0
310	Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study.. Journal of Clinical Oncology, 2013, 31, e14710-e14710.	0.8	0
311	Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3597-3597.	0.8	0
312	Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3571-3571.	0.8	0
313	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. Blood, 2013, 122, 626-626.	0.6	0
314	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 447-447.	0.8	0
315	Outcome after liver transplantation compared with chemotherapy in colorectal cancer patients with nonresectable liver-only disease.. Journal of Clinical Oncology, 2014, 32, 531-531.	0.8	0
316	FCÎ³RIIa and FCÎ³RIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 3573-3573.	0.8	0
317	Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFBR expression and low vessel density as independent prognosis markers for stage IV CRC.. Journal of Clinical Oncology, 2014, 32, e14525-e14525.	0.8	0
318	Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2014, 32, 3590-3590.	0.8	0
319	C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.. Journal of Clinical Oncology, 2015, 33, 3548-3548.	0.8	0
320	Radiation therapy in upper GI tract tumours. Acta Chirurgica Scandinavica Supplementum, 1988, 541, 32-8.	0.1	0
321	Which rectal cancers are locally advanced?. Oncology, 2012, 26, 743, 746, 751-2.	0.4	0